Comparative Analysis of Niosomal Mefloquine and Cisplatin on Apoptosis and Angiogenesis in Breast Cancer: Insights from In Vitro and In Silico Studies - Summary - MDSpire
Advertisement
Comparative Analysis of Niosomal Mefloquine and Cisplatin on Apoptosis and Angiogenesis in Breast Cancer: Insights from In Vitro and In Silico Studies
To evaluate the combined effects of niosomal mefloquine and cisplatin on apoptosis and angiogenesis in breast cancer cells, particularly focusing on specific mechanisms to overcome drug resistance.
Key Findings:
Cisplatin induces apoptosis through DNA cross-linking but faces resistance mechanisms, highlighting the need for combination therapies.
Mefloquine enhances apoptosis by increasing reactive oxygen species and disrupting lysosomal function, suggesting a novel approach to treatment.
Niosomal formulations improve drug delivery and bioavailability of the combined therapy, potentially leading to better patient outcomes.
Interpretation:
The combination of niosomal mefloquine and cisplatin may synergistically enhance therapeutic efficacy against breast cancer by targeting multiple pathways involved in apoptosis and angiogenesis, which could lead to improved treatment protocols.
Limitations:
The study primarily focuses on in vitro and in silico models, which may not fully replicate in vivo conditions, indicating a need for caution in translating results to clinical settings.
Further clinical studies are needed to validate the findings and assess safety and efficacy in humans, emphasizing the importance of real-world data.
Conclusion:
Combining niosomal mefloquine with cisplatin presents a promising strategy to enhance treatment outcomes in breast cancer, particularly in overcoming drug resistance, and warrants further investigation.
by Zohreh Salari, Ahmad Khosravi, Arezo Riahi, Elaheh Molaakbari, Ehsan Salarkia, Ali Reza Keyhani, Samira Sohbati, Ghazal Mansouri, Mina Khosravi, Mohammad Zarif, Mohammad Amin Raeisi Estabragh
